Literature DB >> 20844189

OX40 ligand regulates inflammation and mortality in the innate immune response to sepsis.

Matthew Karulf1, Ann Kelly, Andrew D Weinberg, Jeffrey A Gold.   

Abstract

The initial phase of sepsis is characterized by massive inflammatory cytokine production that contributes to multisystem organ failure and death. Costimulatory molecules are a class of receptors capable of regulating cytokine production in adaptive immunity. Recent studies described their presence on neutrophils and monocytes, suggesting a potential role in the regulation of cytokine production in innate immunity. The purpose of this study was to determine the role for OX40-OX40 ligand (OX40L) interaction in the innate immune response to polymicrobial sepsis. Humans with sepsis demonstrated upregulation of OX40L on monocytes and neutrophils, with mortality and intensive care unit stay correlating with expression levels. In an animal model of polymicrobial sepsis, a direct role for OX40L in regulating inflammation was indicated by improved survival, decreased cytokine production, and a decrease in remote organ damage in OX40L(-/-) mice. The finding of similar results with an OX40L Ab suggests a potential therapeutic role for OX40L blockade in sepsis. The inability of anti-OX40L to provide significant protection in macrophage-depleted mice establishes macrophages as an indispensable cell type within the OX40/OX40L axis that helps to mediate the clinical signs of disease in sepsis. Conversely, the protective effect of anti-OX40L Ab in RAG1(-/-) mice further confirms a T cell-independent role for OX40L stimulation in sepsis. In conclusion, our data provide an in vivo role for the OX40/OX40L system in the innate immune response during polymicrobial sepsis and suggests a potential beneficial role for therapeutic blockade of OX40L in this devastating disorder.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20844189      PMCID: PMC3622718          DOI: 10.4049/jimmunol.1000404

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  32 in total

Review 1.  TNF superfamily in inflammatory disease: translating basic insights.

Authors:  Michael Croft; Wei Duan; Heonsik Choi; So-Young Eun; Shravan Madireddi; Amit Mehta
Journal:  Trends Immunol       Date:  2011-12-13       Impact factor: 16.687

Review 2.  Science gone translational: the OX40 agonist story.

Authors:  Andrew D Weinberg; Nicholas P Morris; Magdalena Kovacsovics-Bankowski; Walter J Urba; Brendan D Curti
Journal:  Immunol Rev       Date:  2011-11       Impact factor: 12.988

3.  CD134 plus CD137 dual costimulation induces Eomesodermin in CD4 T cells to program cytotoxic Th1 differentiation.

Authors:  Harry Z Qui; Adam T Hagymasi; Suman Bandyopadhyay; Marie-Clare St Rose; Raghunath Ramanarasimhaiah; Antoine Ménoret; Robert S Mittler; Scott M Gordon; Steven L Reiner; Anthony T Vella; Adam J Adler
Journal:  J Immunol       Date:  2011-08-31       Impact factor: 5.422

Review 4.  Advances in targeted therapy for malignant lymphoma.

Authors:  Li Wang; Wei Qin; Yu-Jia Huo; Xiao Li; Qing Shi; John E J Rasko; Anne Janin; Wei-Li Zhao
Journal:  Signal Transduct Target Ther       Date:  2020-03-06

Review 5.  Phenotype and function of tumor-associated neutrophils and their subsets in early-stage human lung cancer.

Authors:  Evgeniy B Eruslanov
Journal:  Cancer Immunol Immunother       Date:  2017-03-10       Impact factor: 6.968

6.  Restraint stress differentially regulates inflammation and glutamate receptor gene expression in the hippocampus of C57BL/6 and BALB/c mice.

Authors:  Monica Sathyanesan; Jacob M Haiar; Michael J Watt; Samuel S Newton
Journal:  Stress       Date:  2017-03-08       Impact factor: 3.493

Review 7.  Co-stimulatory and co-inhibitory pathways in cancer immunotherapy.

Authors:  Rachel E O'Neill; Xuefang Cao
Journal:  Adv Cancer Res       Date:  2019-04-17       Impact factor: 6.242

Review 8.  ATVB Distinguished Scientist Award: How Costimulatory and Coinhibitory Pathways Shape Atherosclerosis.

Authors:  Klaus Ley; Norbert Gerdes; Holger Winkels
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-03-30       Impact factor: 8.311

Review 9.  Advances in targeted therapy for malignant lymphoma.

Authors:  Li Wang; Wei Qin; Yu-Jia Huo; Xiao Li; Qing Shi; John E J Rasko; Anne Janin; Wei-Li Zhao
Journal:  Signal Transduct Target Ther       Date:  2020-03-06

10.  The upregulated expression of OX40/OX40L and their promotion of T cells proliferation in the murine model of asthma.

Authors:  Wei Lei; Da-Xiong Zeng; Can-Hong Zhu; Gao-Qin Liu; Xiu-Qin Zhang; Chang-Guo Wang; Qin Wang; Jian-An Huang
Journal:  J Thorac Dis       Date:  2014-07       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.